Programmed death-ligand 1 [PD-(L) 1], cytotoxic T-lymphocyte associated protein 4 (CTLA-
4), and lymphocyte-activation gene 3 (LAG-3) inhibitors are recent breakthroughs in cancer …

Simple Summary Although the incorporation of immune checkpoint inhibitors (ICIs) in
melanoma treatment has significantly improved prognosis for patients with advanced …

Chimeric antigen receptor T-cell (CAR-T cell) therapy directed at CD19 produces durable
remissions in the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL) …

Immuno-oncology has revolutionized the treatment of metastatic non-small cell lung cancer
(mNSCLC) since the approval of immunotherapy by the US FDA in 2015. Despite the …

Signal transducer and activator of transcription 3 (STAT3) is a transcriptional factor involved
in almost all cancer hallmark features including tumor proliferation, metastasis …

The differentiation, survival, and effector function of tumor-specific CD8+ cytotoxic T cells lie
at the center of antitumor immunity. Due to the lack of proper costimulation and the abundant …

Background The immunological checkpoint known as Inducible T Cell Costimulatory Factor
(ICOS, Cluster of Differentiation, CD278) is activated and expressed on T cells. Both somatic …

Simple Summary Immune checkpoint blockade (ICB) with antibodies targeting CTLA-4
(Cytotoxic Lymphocyte Antigen 4) and/or programmed death-1 protein (PD-1)/programmed …

In tumor therapeutics, the transition from conventional cytotoxic drugs to targeted molecular
therapies, such as those targeting receptor tyrosine kinases, has been pivotal. Despite this …

The in-depth characterization of cross-talk between tumor cells and T cells in solid and
hematological malignancies will have to be considered to develop new therapeutical …